Effect of atrial natriuretic peptide on adiponectin in patients with heart failure

European Journal of Heart Failure

Volumn 10, Issue 4, 2008, Pages 360-366

  Tanaka, Toshinari ^a   Tsutamoto, Takayoshi ^a   Sakai, Hiroshi ^a   Nishiyama, Keizo ^a   Fujii, Masanori ^a   Yamamoto, Takashi ^a   Horie, Minoru ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Adiponectin; Atrial natriuretic peptide; Brain natriuretic peptide; Carperitide; Heart failure

Indexed keywords

ADIPONECTIN; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR ALPHA; BRAIN NATRIURETIC PEPTIDE; CATECHOLAMINE; GLYCERYL TRINITRATE; LOOP DIURETIC AGENT;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INFUSION; FEMALE; HEART FAILURE; HEART PROTECTION; HOSPITAL ADMISSION; HUMAN; MALE; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADIPONECTIN; ATRIAL NATRIURETIC FACTOR; BODY MASS INDEX; BRAIN-DERIVED NEUROTROPHIC FACTOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART FAILURE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MOLECULAR WEIGHT; NITROGLYCERIN;

EID: 41449116554     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2008.02.005     Document Type: Article

References (43)

1. Kadowaki T., and Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 26 (2005) 439-451
2. Berg A.H., Combs T.P., and Scherer P.E. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 13 (2002) 84-89
3. Beltowski J. Adiponectin and resistin-new hormones of white adipose tissue. Med Sci Monit 9 (2003) RA55-RA61
4. Shibata R., Ouchi N., Ito M., et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 10 (2004) 1384-1389
5. Shibata R., Sato K., Pimentel D.R., et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 11 (2005) 1096-1103
6. Arita Y., Kihara S., Ouchi N., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1999) 79-83
7. Kumada M., Kihara S., Sumitsuji S., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23 (2003) 85-89
8. Pischon T., Girman C.J., Hotamisligil G.S., et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2004) 1730-1737
9. Hotta K., Funahashi T., Arita Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 (2000) 1595-1599
10. Kenchaiah S., Evans J.C., Levy D., et al. Obesity and the risk of heart failure. N Engl J Med 347 (2002) 305-313
11. von Eynatten M., Hamann A., Twardella D., et al. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin Chem 52 (2006) 853-859
12. Kistorp C., Faber J., Galatius S., et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112 (2005) 1756-1762
13. Tsutamoto T., Tanaka T., Sakai H., et al. Total and high-molecular weight adiponectin, hemodynamics, and mortality in patients with chronic heart failure. Eur Heart J. 28 (2007) 1723-1730
14. Sengenes C., Berlan M., De Glisezinski I., et al. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J 14 (2000) 1345-1351
15. Sengenes C., Bouloumie A., Hauner H., et al. Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J Biol Chem 278 (2003) 48617-48626
16. Moro C., Crampes F., Sengenes C., et al. Atrial natriuretic peptide contributes to physiological control of lipid mobilization in humans. FASEB J 18 (2004) 908-910
17. Tsukamoto O., Asakura M., Minamino T., et al. Brain natriuretic peptide enhances adiponectin production in adipocytes. Circulation 114 (2006) II-486
18. Tsao T.S., Tomas E., Murrey H.E., et al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J Biol Chem 278 (2003) 50810-50817
19. Nakano Y., Tajima S., Yoshimi A., et al. A novel enzyme-linked immunosorbent assay specific for high-molecular-weight adiponectin. J Lipid Res 47 (2006) 1572-1582
20. Pajvani U.B., Hawkins M., Combs T.P., et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279 (2004) 12152-12162
21. Aso Y., Yamamoto R., Wakabayashi S., et al. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 55 (2006) 1954-1960
22. Saito Y., Nakao K., Nishimura K., et al. Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function. Circulation 76 (1987) 115-124
23. Yoshimura M., Yasue H., Morita E., et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 84 (1991) 1581-1588
24. Abraham W.T., Lowes B.D., Ferguson D.A., et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 4 (1998) 37-44
25. Colucci W.S., Elkayam U., Horton D.P., et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 343 (2000) 246-253
26. Ishikawa C., Tsutamoto T., Wada A., et al. Inhibition of aldosterone and endothelin-1 by carperitide was attenuated with more than 1 week of infusion in patients with congestive heart failure. J Cardiovasc Pharmacol 46 (2005) 513-518
27. Hayashi M., Tsutamoto T., Wada A., et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 37 (2001) 1820-1826
28. Tsutamoto T., Wada A., Maeda K., et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96 (1997) 509-516
29. Tentolouris N., Doulgerakis D., Moyssakis I., et al. Plasma adiponectin concentrations in patients with chronic renal failure: relationship with metabolic risk factors and ischemic heart disease. Horm Metab Res 36 (2004) 721-727
30. Zoccali C., Mallamaci F., Tripepi G., et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13 (2002) 134-141
31. Butler J., Forman D.E., Abraham W.T., et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 147 (2004) 331-338
32. Sackner-Bernstein J.D., Skopicki H.A., and Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111 (2005) 1487-1491
33. Baratta R., Amato S., Degano C., et al. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab 89 (2004) 2665-2671
34. Shadid S., Stehouwer C.D., Jensen M.D., et al. Diet/exercise versus pioglitazone: effects of insulin sensitization with decreasing or increasing fat mass on adipokines and inflammatory markers. J Clin Endocrinol Metab 91 (2006) 3418-3425
35. Yang W.S., Lee W.J., Funahashi T., et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86 (2001) 3815-3819
36. Combs T.P., Berg A.H., Rajala M.W., et al. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes 52 (2003) 268-276
37. Shibata R., Sato K., Kumada M., et al. Adiponectin accumulates in myocardial tissue that has been damaged by ischemia-reperfusion injury via leakage from the vascular compartment. Cardiovasc Res 74 (2007) 471-479
38. Furuhashi M., Ura N., Higashiura K., et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42 (2003) 76-81
39. Kurata A., Nishizawa H., Kihara S., et al. Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 70 (2006) 1717-1724
40. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316 (1987) 1429-1435
41. Granger C.B., McMurray J.J., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362 (2003) 772-776
42. Liao Y., Takashima S., Maeda N., et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res 67 (2005) 705-713
43. Ishikawa Y., Akasaka Y., Ishii T., et al. Changes in the distribution pattern of gelatin-binding protein of 28 kDa (adiponectin) in myocardial remodelling after ischaemic injury. Histopathology 42 (2003) 43-52